CAS: 38985-64-7; 2-Fluorophenylisothiocyanate

上下游产品

CAS号348-54-9 邻氟苯胺 | CAS号463-71-8 硫光气 | CAS号75-15-0 二硫化碳 | CAS号51085-49-5 2-氟苯胺盐酸盐 | CAS号32315-10-9 三光气 | CAS号38985-72-7 4-(2-氟苯基)-3-胺基硫脲 | CAS号883-93-2 2-苯基苯并噻唑 | CAS号120-75-2 2-甲基苯并噻唑 | CAS号656-32-6 1-(2-氟苯基)-2-硫脲 | CAS号1629-78-3 2-乙酰苯并噻唑 | CAS号368-05-8 1,3-bis(2-fluor... | CAS号1843-21-6 N-苯基苯并[d]噻唑-2-胺 | CAS号17626-86-7 2-(2-丙基)-1,3-苯并噻唑 | CAS号2851-08-3 2-(1-哌啶基)苯并噻唑 | CAS号62644-13-7 1-(2-fluorophen...

2-氟苯胺 以 二氯甲烷 用作溶剂,化学反应 0.41H,反应生成异硫氰酸(2-氟苯)酯
参考文献:Isothiocyanates (Itcs) 1-(Isothiocyanatomethyl)-4-Phenylbenzene And 1-Isothiocyanato-3,5-Bis(Trifluoromethyl)Benzene-aldehyde Dehydrogenase (Aldh) Inhibitors,Decreases Cisplatin Tolerance And Migratory Ability Of Nsclc
标题:Isothiocyanates (Itcs) 1-(Isothiocyanatomethyl)-4-Phenylbenzene And 1-Isothiocyanato-3,5-Bis(Trifluoromethyl)Benzene-aldehyde Dehydrogenase (Aldh) Inhibitors,Decreases Cisplatin Tolerance And Migratory Ability Of Nsclc
摘要:非小细胞肺癌(nsclc)的主要治疗模式之一是以顺铂为基础的化疗.然而,获得顺铂耐药性仍然是一个主要问题.现有的化疗方案通常对表达醛脱氢酶(aldh)的癌细胞无效.因此,迫切需要针对aldh阳性癌细胞的治疗方法.本研究比较了36种结构多样的异硫氰酸酯(itc)与aldh抑制剂二硫化物(dsf)对nsclc细胞的抗癌性能.使用autodocktools评估它们与aldh同工酶和abc蛋白的潜在亲和力,以选择出三种对所有测试蛋白的亲和力最强的化合物.所选的itc对nsclc细胞的存活率没有影响(在测试浓度下),但显著降低了顺铂耐药变异株a549Cisr和晚期(第四期)nsclc细胞系h1581的顺铂耐受性.此外,长期补充itc 1-异硫氰酸甲基-4-苯基苯烷可逆转a549Cisr的emt表型和迁移潜力,使其达到与母细胞a549相同的水平,增加e-Cadherin表达,随后降低abcc1和aldh3A1的表达.我们的数据表明,Aldh抑制剂dsf和itc是顺铂化疗的潜在辅助治疗药物.
Doi:10.3390/ijms23158644

专利信息

专利号:US-2024215280-A1
优先权日:2022-10-31
标 题:In situ core/shell perovskite nanocrystal material, method of preparation thereof, and light emitting device comprising the same
发明人：LEE TAE-WOO; KIM JOO SUNG
权利人:SEOUL NAT UNIV R&DB FOUNDATION; PEROLED CO LTD
摘要:The present inventive concept relates to an in situ core/shell perovskite nanocrystal film formed by an in situ nanocrystal synthesis process, a method for producing the same, and a light emitting device comprising the same as a light-emitting layer. The in situ core/shell perovskite nanocrystal film formed by the in situ nanocrystal synthesis process according to the present inventive concept exhibits a strong charge confinement effect by nanocrystal formation, and can simultaneously greatly improve the luminescence efficiency and lifetime by maintaining the fast charge transport capability of polycrystalline perovskite.

专利号:US-5998399-A
优先权日:1993-03-23
标题 :Guanidine derivatives useful in therapy as inhibitors of nitric oxide synthetase
发明人：MACDONALD JAMES E; GENTILE ROBERT; MURRAY ROBERT J
权利人:ASTRA AB
摘要:Method of treating or reducing the risk of human disease or condition in which the synthesis or oversynthesis of nitric oxide forms a contributory part wherein a therapeutically effective amount of the compound of formula (I) as defined in the specification is administered to a person suffering from or susceptible to such disease or condition.

专利号:US-2024158692-A1
优先权日:2022-10-31
标题 :In-situ core/shell nanoparticle structured metal halide perovskite luminescent material, light emitting device including the same, and manufacturing method thereof
发明人：LEE TAE-WOO; KIM JOO SUNG
权利人:SEOUL NAT UNIV R&DB FOUNDATION; PEROLED CO LTD
摘要:The present inventive concept relates to an in situ core/shell perovskite nanocrystal film formed by an in situ nanocrystal synthesis process, a method for producing the same, and a light emitting device comprising the same as a light-emitting layer. The in situ core/shell perovskite nanocrystal film formed by the in situ nanocrystal synthesis process according to the present inventive concept exhibits a strong charge confinement effect by nanocrystal formation, and can simultaneously greatly improve the luminescence efficiency and lifetime by maintaining the fast charge transport capability of polycrystalline perovskite.

专利号:CN-114540846-B
优先权日:2022-02-10
标题:Synthesis method of 1,2, 4-triazolo six-membered nitrogen heterocycle-3-amine